Trial shows benefits of targeted drug against early-stage breast cancer with inherited BRCA mutation 03 Jun 2021 Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial. Find out more Show/Hide
Prince of Wales visits the Breast Cancer Now Toby Robins Research Centre at ICR 13 May 2021 Today, His Royal Highness The Prince of Wales visited the Breast Cancer Now Toby Robins Research Centre, at The Institute of Cancer Research, London, 21 years after he officially opened it as the UK’s first dedicated breast cancer research centre in 1999. Find out more Show/Hide
Targeted breast cancer drug – olaparib – given green light by EU 16 Apr 2019 European Medicines Agency approves olaparib for women with BRCA-mutant breast cancer – 15 months after licensing in the US. Find out more Show/Hide
Targeting chemotherapy with genetic testing provides effective treatment for women with aggressive breast cancer 30 Apr 2018
The ICR responds to the FDA approval of olaparib for women with BRCA-mutant advanced breast cancer 12 Jan 2018